Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation

Blood

Volumn 87, Issue 6, 1996, Pages 2195-2204

  Slavin, Shimon ^a   Naparstek, Elizabeth ^a   Nagler, Arnon ^a   Ackerstein, Aliza ^a   Samuel, Simcha ^a   Kapelushnik, Joseph ^a   Brautbar, Chaim ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER THERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0029868846     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2195.bloodjournal8762195     Document Type: Article

References (76)

1. Thomas ED: The role of marrow transplantation in the eradication of malignant disease Cancer 49:1963, 1963
2. O'Reilly RJ: Allogeneic bone marrow transplantation: Current status and future directions. Blood 62:941, 1983
3. Barrett AJ, Horowitz MM, Gale RP, Biggs, JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB: Marrow transplantation for acute lymphoblastic leukemia. Factors affecting relapse and survival. Blood 74:862, 1989
4. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas, ED: Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529, 1981
5. Weiden PL, Fluornoy N, Sanders JE, Sullivan KM, Thomas ED: Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation 13:248, 1981
6. Sullivan KM, Weiden PL, Storb R, Witterspoon RP, Fefer A, Fisher L, Bucker CD, Anasett C, Appelbaum FR, Badger C: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720, 1989
7. Horowitz M, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
8. Sinkovics JG, Shullenberger CC: Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia. Proc Am Assoc Cancer Res 4:62, 1963
9. Boranic M, Tonkovic I: Time pattern of the antileukemia effect of graft-versus-host reaction in mice. I. Cellular events. Cancer Res 31:1140, 1971
10. Bortin MM, Truitt RL, Rimm AA, Bach FH: Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 281:490, 1979
11. Slavin S, Weiss L, Morecki S, Weigensberg M: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155, 1981
12. Truitt RL, Shih F-H, LeFever AV, Tempelis LD, Andreani M, Bortin MM: Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 131:2050, 1983
13. Meredith RF, O'Kunewick JP: Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation 35:378, 1983
14. Weiss L, Weigensberg M, Morecki S, Bar S, Cobbold S, Waldmann H, Slavin S: Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother 31:236, 1990
15. Truitt RL, Atasoylu AA: Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 77:2515, 1991
16. Weiss L, Reich S, Slavin S: Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 10:19, 1992
17. Slavin S, Or R, Naparstek W, Ackerstein A, Weiss L: Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72:407a, 1988 (suppl 1; abstr)
18. Slavin S, Ackerstein A, Kedar E, Weiss L: IL-2 activated cell-mediated immunotherapy: Control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL2. Bone Marrow Transplant 6:86, 1990 (suppl 1)
19. Slavin S, Or R, Naparstek E, Kapelushnik Y, Weiss L, Ackerstein A, Vourka-Karussis U, Nagler A: Eradication of minimal residual disease (MRD) following autologous (ABMT) and allogeneic bone marrow transplantation (BMT) by cytokine-mediated immunotherapy (CMI) and cell-mediated cytokine-activated immunotherapy (CCI) in experimental animals and man. Blood 80:535a, 1992 (abstr)
20. Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10.221, 1992
21. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Drakos P, Or R: Graft vs leukemia (GVL) effects with controlled GVHD by cell mediated immunotherapy (CMI) following allogeneic bone marrow transplantation (BMT). Blood 82:423a, 1993 (abstr)
22. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone barrow transplantation. Blood 79:517, 1992
23. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994
24. Waldmann H, Polliack A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C: Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAM-PATH-1). Lancet 2:483, 1984
25. Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Ben Shahar M, Slavin S: Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine mediated immunotherapy with recombinant human interferon-2a and interleukin-2. Cancer Immunol Immunother 35:401, 1992
26. Naparstek E, Hardan I, Ben-Shahar M, Cohen P, Mumcuoglu M, Samuel S, Weiss L, Hale G, Waldmann H, Slavin S: A new method for prevention of graft vs host disease (GVHD). Exp Hematol 17:723, 1989 (abstr)
27. Hale G, Waldmann H: Campath-1 monoclonal antibodies in bone marrow transplantation. J Hematotherapy 3:15, 1994
28. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85:5698, 1988
29. Gubbay I, Collignon J, Koopman P, Blanche C, Economou A, Munsterberg A, Vivian N, Goodfellow P, Lovell-Badge R. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryologically expressed genes. Nature 346:245, 1990
30. Pugatsch T, Oppenheim A, Slavin S: Improved single step PCR assay for sex-mismatched BMT. (in press)
31. Slavin S, Ackerstein A, Weiss L: Adoptive immunotherapy in conjunction with bone marrow transplantation - Amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul 7:180, 1988
32. Weiss L, Lubin I, Factorowich Y, Lapidot Z, Reich S, Reisner Y, Slavin S: Effective graft vs leukemia effects independently of graft-vs-host disease following T-cell depleted allogeneic bone marrow transplantation in a murine model of B-cell leukemia/lymphoma (BCLI); role of cell therapy and rIL-2. J Immunol 153:2562, 1994
33. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S: Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 23:196, 1995
34. Barrett AJ, Horowitz MM, Gale RP, et al: Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 74:862, 1989
35. Ringden O, Horowitz MM; for the Advisory Committee of the International BMT Registry: Graft-versus-leukemia reactions in humans. Transplant Proc 21:2989, 1989
36. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989
37. Collins RH, Rogers ZR, Bennett M, Kurser V, Nikein A, Fay JW: Hematologic relapse of chronic myelogenous leukemia following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391, 1992
38. Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, Tedone E, Frasboni F, Tong J, Marmont AM: Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77:1423, 1991
39. Stockschlaeder M, Storb R, Pepe M, Longton G, McDonald G, Anasetti C, Appelbaum F, Doney K, Martin P, Sullivan K: A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haemat 80:49, 1992
40. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB: Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-ver-sus-leukaemia reaction" in man? Lancet 2:537, 1978
41. Higano CS, Brixey M, Bryant EM: Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 50:175, 1990
42. Weiss L, Reich S, Slavin S: Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 6:229, 1990
43. Kolb HJ, Mittermueller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
44. Frassoni F, Fagioli F, Sessarego M, Gualandi MT, van Lint T, Lamparelli T, Occhini D, Figari O, Valbonesi M, Bacigalupo A: The effect of donor leukocyte infusion for CML patients relapsed after allogeneic BMT. 18th Annual Meeting of the European Bone Marrow Transplant Group, Stockholm, Sweden, 1992 (abstr 248)
45. Frassoni F, Fagioli F, Sessarego M, Gualandi MT, van Lint T, Lamparelli T, Occhini D, Figari O, Valbonesi M, Bacigalupo A: The effect of donor leukocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp Hematol 20:712, 1992 (abstr)
46. Schattenberg A, Bar B, Preijers F, Menisink E, Raymakers R, De Witte T: Treatment of relapse in recipients of lymphocyte depleted bone marrow with retransplantation of unmanipulated grafts or with infusion of donor lymphocytes. 18th Annual Meeting of the European Bone Marrow Transplant Group, Stockholm, Sweden, 1992 (abstr 363)
47. De Witte T, Schattenberg A, Preijers F, Mensink E: Treatment of relapse in recipients of lymphocyte depleted grafts with infusion of lymphocytes of the original bone marrow donor. Exp Hematol 20:723, 1992 (abstr)
48. Bar BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, Linders EH, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513, 1993
49. Lonnqvist B, Ljungman P, Caneskog J, Ringden O, Shanwell A, Gahrton G: Treatment of relapsed myeloproliferative disease after BMT with donor-lymphocyte transfusions. 18th Annual Meeting of the European Bone Marrow Transplant Group, Stockholm, Sweden, 1992 (abstr 263)
50. Kofuru PR, Filippa DA, Richardson ME, Jhanwar SC, Chagnati SR, Koziner B, Clarkson BD, Leiberman PH, Chaganti RS: Cytogenetic and histologic correlations in malignant lymphoma. Blood 69:97, 1987
51. Drobyski WR, Roth MS, Thibodeau SN, Gorrschall JL: Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 10:301, 1992
52. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van-Tuinen P, Horowitz MM: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
53. Helg C, Soulier-Lauper M, Guetty-Alberto M, Cabrol C, Roux E, Beris P, Jeannet M, Quintero A, Chapuis B: Induction of graft-versus-leukemia reaction with graft-versus-host disease for recurrent chronic myelogenous leukemia after T-cell depleted allogeneic bone marrow transplantation. 18th Annual Meeting of the European Bone Marrow Transplant Group, Stockholm, Sweden, 1992 (abstr 481)
54. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125, 1993
55. Jiang JZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ: T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 11:133, 1993
56. Novotny J, Hertenstein B, Bunjes D: Patient with relapse of CML after allogeneic bone marrow transplantation receiving interferon alpha and donor buffy coat transfusions became negative for bcr/abl transcript (RT/PCR). Chronic Myeloid Leukemia Second International Conference, 1992 (abstr 277)
57. Hertenstein B, Wiesneth M, Novotny J: Interferon alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant (in press)
58. Collins R, Pineiro L, Lanier A, Fay J: Immunomodulation resulting in complete remission in patients (PTS) with residual or relapsed malignancy after allogeneic bone marrow transplantation (BMT). Blood 82:417a, 1993 (suppl 1; abstr)
59. van Rhee F, Cullis JO, Lin F, Cross NCP, Goldman JM. Donor leukocyte transfusions (DLT) for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant. Blood 82:416a, 1993 (suppl 1; abstr)
60. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood 83:3377, 1994
61. Porter DL, Roth MS, McGarigle C, Ferrara LM: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
62. Leber B, Walker IR, Rodrigues A, McBride JA, Carter R, Brian MC: Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant 12:405, 1993
63. Klingbiel T, Handgretinger R, Ehninger G, Dopfer R, Brand A, ten Bosch GJA, Kompf R, Niethammer D: Adoptive immunotransfer after bone marrow transplantation from an unrelated donor leads to remission of T-ALL. 18th Annual Meeting of the European Bone Marrow Transplant Group, Stockholm, Sweden, 1992 (abstr 67)
64. Papadopoulos EB, Ladanyi M, Emanual D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho-proliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185, 1994
65. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 11:109, 1993
66. Kolb HJ, Mittermuller J, Hertenstein B, deWitte T, Verdonck W, Ljungman P, Gratwohl A: Graft-versus-leukemia reaction in patients receiving buffy coat transfusions from their marrow donor for treatment of recurrent leukemia after marrow transplantation. 19th Annual Meeting of the European Bone Marrow Transplant Group, 1993 (abstr 1605)
67. Kolb HJ, de Witte T, Mittermuller J, Hertenstein B, Goldman JM, Ljungman P, Verdonck L, Holler E, Thalmaier K, Bartram C: Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation Blood 82:214a, 1993 (suppl 1)
68. Slavin S, Fuks Z, Kaplan HS, Strober S: Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 147:963, 1978
69. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker NM, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar H, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995
70. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: Hypothesis: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
71. Ackerstein A, Kedar E, Slavin S: Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood 78:1212, 1991
72. Barrett AJ, Jiang YZ, Kanfer EJ, Gordon AA: T cell clones with cytotoxicity to CML cells exert leukaemia-specific cytokine-mediated suppression of chronic myeloid leukaemia (CML) CFU-GM. Exp Hematol 20:723, 1992
73. BCR-ABL protein. Proc Natl Acad Sci USA 89:1468, 1992
74. Van Lochem E, De Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic-T cell activities. Bone Marrow Transplant 10:181, 1992
75. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329, 1993
76. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828, 1989